Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955050005> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W2955050005 endingPage "S285" @default.
- W2955050005 startingPage "S285" @default.
- W2955050005 abstract "Eptinezumab, a selective and potent anti-CGRP monoclonal antibody, demonstrated significant reductions in mean monthly migraine days (MMDs) in episodic migraine (EM) and chronic migraine (CM) trials. This analysis evaluated the changes in HRQoL by the magnitude of migraine response in adults with EM or CM in trials of eptinezumab. Adults with EM or CM were randomized to eptinezumab 100mg, 300mg, or placebo (or 30mg in EM trial) administered intravenously every 12 weeks (Wks). HRQoL was evaluated descriptively using the Physical Component Summary (PCS) and Mental Component Summary (MCS) scores of Short-Form Health Survey v2.0 (4-wk recall) at baseline and Wk4. Patients were stratified by ≥50% or ≥75% migraine response by Wk4 (Month 1). In patients with CM, early ≥50% migraine response was associated with clinically meaningful improvements in PCS and MCS scores at Wk4, ranging from +4.5 to +6.6 and +1.7 to +5.2, respectively. PCS and MCS improvements were generally greater among ≥75% migraine responders as compared to ≥50% migraine responders (PCS: range, +4.4 to +7.5; MCS: range, +1.6 to +5.9). In patients with EM, early ≥50% migraine response was associated with incremental improvements in PCS and MCS, ranging from +2.2 to +3.4 and +1.2 to +2.2, respectively. MCS improvements were similar and PCS improvements greater among ≥75% migraine responders as compared to ≥50% migraine responders (PCS: range, +3.1 to +4.2; MCS: range, +1.2 to +2.7). Eptinezumab treatment was associated with positive HRQoL gains. Patients achieving meaningful reductions in MMDs (≥50% or ≥75%) by Month 1 after treatment experienced meaningful improvements in PCS and MCS for patients with CM and numerical improvements in patients with EM. Greater MMD reductions observed with eptinezumab vs placebo were generally associated with incremental PCS and MCS gains, indicative of HRQoL improvements beyond reduction in MMDs." @default.
- W2955050005 created "2019-07-12" @default.
- W2955050005 creator A5002946605 @default.
- W2955050005 creator A5018696211 @default.
- W2955050005 creator A5045253087 @default.
- W2955050005 creator A5064341657 @default.
- W2955050005 creator A5067093883 @default.
- W2955050005 creator A5084396069 @default.
- W2955050005 date "2019-05-01" @default.
- W2955050005 modified "2023-10-17" @default.
- W2955050005 title "PND80 RAPID MIGRAINE RESPONSE BY MONTH 1 AND CLINICALLY MEANINGFUL IMPROVEMENTS IN HEALTH RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH MIGRAINE IN PHASE 3 TRIALS OF EPTINEZUMAB" @default.
- W2955050005 doi "https://doi.org/10.1016/j.jval.2019.04.1353" @default.
- W2955050005 hasPublicationYear "2019" @default.
- W2955050005 type Work @default.
- W2955050005 sameAs 2955050005 @default.
- W2955050005 citedByCount "0" @default.
- W2955050005 crossrefType "journal-article" @default.
- W2955050005 hasAuthorship W2955050005A5002946605 @default.
- W2955050005 hasAuthorship W2955050005A5018696211 @default.
- W2955050005 hasAuthorship W2955050005A5045253087 @default.
- W2955050005 hasAuthorship W2955050005A5064341657 @default.
- W2955050005 hasAuthorship W2955050005A5067093883 @default.
- W2955050005 hasAuthorship W2955050005A5084396069 @default.
- W2955050005 hasBestOaLocation W29550500051 @default.
- W2955050005 hasConcept C126322002 @default.
- W2955050005 hasConcept C142724271 @default.
- W2955050005 hasConcept C159110408 @default.
- W2955050005 hasConcept C1862650 @default.
- W2955050005 hasConcept C204787440 @default.
- W2955050005 hasConcept C27081682 @default.
- W2955050005 hasConcept C2778541695 @default.
- W2955050005 hasConcept C2779951463 @default.
- W2955050005 hasConcept C2910587157 @default.
- W2955050005 hasConcept C535046627 @default.
- W2955050005 hasConcept C71924100 @default.
- W2955050005 hasConceptScore W2955050005C126322002 @default.
- W2955050005 hasConceptScore W2955050005C142724271 @default.
- W2955050005 hasConceptScore W2955050005C159110408 @default.
- W2955050005 hasConceptScore W2955050005C1862650 @default.
- W2955050005 hasConceptScore W2955050005C204787440 @default.
- W2955050005 hasConceptScore W2955050005C27081682 @default.
- W2955050005 hasConceptScore W2955050005C2778541695 @default.
- W2955050005 hasConceptScore W2955050005C2779951463 @default.
- W2955050005 hasConceptScore W2955050005C2910587157 @default.
- W2955050005 hasConceptScore W2955050005C535046627 @default.
- W2955050005 hasConceptScore W2955050005C71924100 @default.
- W2955050005 hasLocation W29550500051 @default.
- W2955050005 hasOpenAccess W2955050005 @default.
- W2955050005 hasPrimaryLocation W29550500051 @default.
- W2955050005 hasRelatedWork W2907279008 @default.
- W2955050005 hasRelatedWork W2909305492 @default.
- W2955050005 hasRelatedWork W2945688603 @default.
- W2955050005 hasRelatedWork W2955283194 @default.
- W2955050005 hasRelatedWork W2998485214 @default.
- W2955050005 hasRelatedWork W3015996685 @default.
- W2955050005 hasRelatedWork W3094653551 @default.
- W2955050005 hasRelatedWork W4206427645 @default.
- W2955050005 hasRelatedWork W4213312366 @default.
- W2955050005 hasRelatedWork W4221124466 @default.
- W2955050005 hasVolume "22" @default.
- W2955050005 isParatext "false" @default.
- W2955050005 isRetracted "false" @default.
- W2955050005 magId "2955050005" @default.
- W2955050005 workType "article" @default.